STOCK TITAN

Belite Bio to Participate in the BTIG Virtual Biotechnology Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company developing treatments for degenerative retinal diseases, announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025.

The company's executive management team will be available for one-on-one meetings with investors during the conference, which can be arranged through BTIG representatives.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction – BLTE

+4.42%
1 alert
+4.42% News Effect

On the day this news was published, BLTE gained 4.42%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will be participating in the BTIG Virtual Biotechnology Conference being held July 29-30, 2025.

To schedule a one-on-one meeting with management, please reach out to your BTIG representative.

About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on XInstagramLinkedIn, and Facebook or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com


FAQ

When is Belite Bio (BLTE) presenting at the BTIG Virtual Biotechnology Conference?

Belite Bio will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025.

How can investors schedule meetings with Belite Bio management at the BTIG conference?

Investors can schedule one-on-one meetings with Belite Bio management by contacting their BTIG representative.

What is Belite Bio's (BLTE) main business focus?

Belite Bio is a clinical-stage drug development company focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs.

Where is Belite Bio (BLTE) headquartered?

Belite Bio is headquartered in San Diego.
Belite Bio, Inc

NASDAQ:BLTE

BLTE Rankings

BLTE Latest News

BLTE Latest SEC Filings

BLTE Stock Data

6.79B
19.91M
Biotechnology
Healthcare
Link
United States
San Diego